Novartis, Amgen in legal battle over Aimovig collaboration

Almost one year after the launch of migraine therapy Aimovig erenumab-aooe, Novartis has filed a lawsuit alleging that its partner Amgen is trying to illegally back out of its deal, prompting Amgen to counter sue. The cases were filed in the U.S. District Court Southern District of New York.

Aimovig became the first calcitonin gene-related peptide (CGRP) inhibitor approved by FDA for migraine in May 2018. Novartis AG (NYSE:NVS; SIX:NOVN) and Amgen Inc. (NASDAQ:AMGN) have been collaborating on development and commercialization of Aimovig since 2015...